Abstract-Loss of peroxisome proliferator-activated receptor-γ (PPARγ) function causes hypertension, whereas its activation lowers blood pressure. Evidence suggests that these effects may be attributable to PPARγ activity in the vasculature. However, the specific transcriptional targets of PPARγ in vessels remain largely unidentified. In this study, we examined the role of smooth muscle PPARγ during salt-sensitive hypertension and investigated its transcriptional targets and functional effect. Transgenic mice expressing dominant-negative PPARγ (S-P467L) in smooth muscle cells were more prone to deoxycorticosterone acetate-salt-induced hypertension and mesenteric arterial dysfunction compared with nontransgenic controls. Despite similar morphometry at baseline, vascular remodeling in conduit and small arteries was enhanced in S-P467L after deoxycorticosterone acetate-salt treatment. Gene expression profiling in aorta and mesenteric arteries revealed significantly decreased expression of tissue inhibitor of metalloproteinase-4 (TIMP-4) in S-P467L. Expression of TIMP-4 was increased by deoxycorticosterone acetate-salt treatment, but this increase was ablated in S-P467L. Interference with PPARγ activity either by treatment with a PPARγ inhibitor, GW9662, or by expressing P467L PPARγ markedly suppressed TIMP-4 in primary smooth muscle cells. PPARγ binds to a PPAR response element (PPRE) in chromatin close to the TIMP-4 gene in smooth muscle cells, suggesting that TIMP-4 is a novel target of PPARγ. The interference with PPARγ and decrease in TIMP-4 were accompanied by an increase in total matrix metalloproteinase activity. PPARγ-mediated loss of TIMP-4 increased, whereas overexpression of TIMP-4 decreased smooth muscle cell migration in a scratch assay. Our findings highlight a protective mechanism induced by PPARγ in deoxycorticosterone acetate-salt treatment, establishing a novel mechanistic link between PPARγ and TIMP-4. 
T hiazolidinediones are high-affinity synthetic ligands of peroxisome proliferator-activated receptor-γ (PPARγ), a transcription factor of the nuclear hormone receptor superfamily. PPARγ is expressed in adipose tissue, where it regulates gene targets to mediate adipogenesis and fatty acid metabolism. Expression of PPARγ in the vasculature suggests potential cardiovascular actions of PPARγ; however, the mechanisms involved remain elusive. In addition to unparalleled effectiveness for improving glycemic control in type 2 diabetes mellitus, thiazolidinediones have been shown to lower blood pressure (BP) and prevent vascular disease. 1, 2 Antihypertensive effects of thiazolidinediones occur in the face of an increase in water and salt reabsorption by the kidney, suggesting robust vascular actions of PPARγ. 3, 4 Perhaps, the most intriguing evidence underscoring the significance of PPARγ in BP regulation is from patients with PPARγ mutations. People harboring these mutations (P467L, V290M, R165T, and L339X) develop lipodystrophy and severe hypertension because of the loss of or interference with PPARγ activity. 5, 6 Similarly, knockin mice carrying the mouse equivalent of one of the human mutations (P465L) exhibit hypertension and cerebral vascular dysfunction, hypertrophy, and remodeling, independent of insulin resistance.
genes. We propose that PPARγ regulates vascular function by altering the expression of genes within the vascular wall. Indeed, we reported that a wide array of genes was induced by a PPARγ agonist, whereas it is being repressed by dominantnegative PPARγ in mouse aorta. 8 To explore the cell-specific actions of PPARγ, we generated a mouse model harboring dominant-negative PPARγ (human PPARγ P467L), the same mutation that causes human hypertension, under control of the smooth muscle myosin heavy chain promoter (termed S-P467L). Our data indicate that smooth muscle PPARγ is critical in regulating vascular function in conduit and resistance arteries. [9] [10] [11] [12] Using gene expression profiling and extensive target validation, we identified RhoBTB1 and regulator of G-protein signaling 5 as novel PPARγ targets in the blood vessel. 10, 11 However, other PPARγ target genes in cardiovascular tissues remain largely unexplored. More importantly, their functional roles during disease conditions need to be examined.
Herein, we tested the hypothesis that smooth muscle PPARγ protects against deoxycorticosterone acetate (DOCA)-salt-mediated hypertension and resistance vessel dysfunction. We used mild DOCA-salt hypertension to unmask the genetic predisposition caused by the loss of smooth muscle PPARγ. Our findings uncovered tissue inhibitor of metalloproteinases (TIMP)-4 as a novel PPARγ target and highlight the protective mechanism of PPARγ during hypertension.
Methods
Pressurized myograph, quantitative real-time reverse transcription polymerase chain reaction, primary cell culture studies, Western blotting, in situ zymography, chromatin immunoprecipitation, and scratch assay were performed as described in the online-only Data Supplement.
Animals
Transgenic mice (age, 4-5 months) carrying a dominant-negative PPARγ P467L mutation under the control of smooth muscle myosin heavy chain promoter (S-P467L) were used. 9 Male mice were used because the BP rise in female mice is slower and less pronounced with DOCA-salt. 13 Mice were subcutaneously implanted with DOCA pellet (50 mg) and allowed ad libitum 0.15 mol/L NaCl for 21 days in addition to regular chow and water. Arterial BP was measured using radiotelemetry. 9 Care of the mice met the standards set forth by the National Institutes of Health guidelines for the care and use of experimental animals. All procedures were approved by the University of Iowa Animal Care and Use Committee.
Data Analysis and Statistics
Data were expressed as mean±SEM and analyzed with SigmaStat (Systat Software). Repeated-measures 2-way ANOVA using Bonferroni post hoc tests for multiple comparisons was used for vascular reactivity data. Student t test was used as required. Gene expression changes were calculated by the Livak method.
14 P≤0.05 was considered significant.
Results
A significant increase in heart and kidney weights was observed in nontransgenic and S-P467L mice after DOCAsalt. There was no difference in body, heart, or kidney weights between genotypes either before or after DOCA-salt treatment (Table S1 in the online-only Data Supplement). Renal renin mRNA was robustly suppressed after DOCA-salt treatment in both groups ( Figure S1 ).
Arterial pressure was similar in both nontransgenic and S-P467L mice at baseline ( Figure 1A ). This differed from previous cohorts of S-P467L mice, which exhibited a modest increase in baseline arterial pressure. 9, 10, 15 After DOCA-salt treatment, there was an increase in mean arterial pressure in both nontransgenic and S-P467L mice, but the DOCA-saltinduced increase in mean arterial pressure in S-P467L was significantly greater than that in nontransgenic ( Figure 1A ). The peak in mean arterial pressure at midnight was significantly higher in S-P467L after DOCA-salt treatment (mean arterial pressure [mm Hg]; nontransgenic mice=140.5±2.6, n=13; S-P467L=156.9±4.6, n=11; P=0.004). As reported previously, S-P467L mice exhibited tachycardia because of impaired baroreflex regulation. 15 DOCA-salt treatment resulted in a similar degree of bradycardia in both groups ( Figure 1B ).
Vasodilation to acetylcholine was slightly impaired in S-P467L mesenteric arteries (MA) at baseline, and this effect was further exaggerated after DOCA-salt treatment ( Figure  S2A ). The maximum response to acetylcholine in S-P467L was significantly decreased after DOCA-salt treatment (E max , nontransgenic mice=82±3.8% and S-P467L=50±12.5%; P<0.05). Vasodilation to nitroprusside was normal in all groups ( Figure S2B ). Middle cerebral arteries from S-P467L mice exhibited a similar impairment in acetylcholine-mediated vasodilation ( Figure S2C ).
Neither ET-1 transcript nor ET-1-induced vasoconstriction differed between nontransgenic and S-P467L ( Figure  S3A ). In both genotypes, DOCA-salt led to a robust increase in plasma arginine vasopressin, measured by the C-terminal portion of arginine vasopressin precursor, Copeptin ( Figure  S3B ). 16 Arginine vasopressin-induced vasoconstriction in S-P467L was modestly reduced with DOCA-salt ( Figure  S3C ). Thus, the exaggerated sensitivity to DOCA-saltinduced hypertension in S-P467L is unlikely to be because of ET-1 or arginine vasopressin. Vasoconstriction to KCl and phenylephrine was similar between genotypes ( Figure S3D and S3E).
A previous study reported an upregulation of local reninangiotensin system components from hypertensive patients carrying the R165T and L339X mutations in PPARγ. 6 However, there was no change in aortic expression of angiotensinogen, renin, angiotensin II type IA receptor, nor angiotensin II type 1B receptor in S-P467L at baseline or after DOCA-salt treatment ( Figure S4 ).
There was no difference in aortic morphometry between genotypes at baseline ( Figure S5 ). However, wall thickness in aorta from S-P467L mice was markedly increased after DOCA-salt treatment ( Figure 2A ). Similarly, there was a significant increase in wall thickness and the media/lumen ratio ( Figure 2B ), and a trend toward an increase in media crosssectional area of small blood vessels in DOCA-salt treated S-P467L, despite similar morphometry of small arteries under baseline conditions. 11 These data suggest that the loss of smooth muscle PPARγ function facilitates vascular remodeling in hypertension.
We investigated the expression of matrix metalloproteinases (MMPs) and their endogenous inhibitors, TIMPs, as they are reported to participate in vascular remodeling in hypertension. 17, 18 A significant increase in MMP-9, but not MMP-2, mRNA was observed in S-P467L arteries after DOCA-salt treatment ( Figure 3A) . Notably, there was a significant decrease in TIMP-4 mRNA in arteries from DOCA-salt-treated S-P467L, whereas the expression of other TIMPs was unchanged ( Figure 3B ). This is consistent with a reanalysis of our published microarray datasets (National Center for Biotechnology Information accession GSE37195 and GSE36482) showing a significant decrease in TIMP-4 mRNA in aorta and MA from S-P467L mice ( Figure 3C ). There was a significant downregulation in TIMP-4 expression in small arteries from S-P467L at baseline ( Figure 3D ). TIMP-4 mRNA expression was increased in nontransgenic arteries after DOCA-salt treatment, but this increase was severely blunted in S-P467L mice ( Figure 3D ).
GW9662, a PPARγ inhibitor, decreased TIMP-4 protein expression in primary vascular smooth muscle cells (SMCs), suggesting that the decrease in TIMP-4 expression in S-P467L mice was attributable to interference with PPARγ ( Figure 4A ). This effect was only consistently observed with 10 μmol/L, possibly because of the short half-life of GW9662 in cell culture. 19 To exclude PPARγ-independent mechanisms, we demonstrated that expression of TIMP-4 was markedly suppressed in SMCs transiently transduced with adenovirus-encoding P467L PPARγ (Ad-P467L; Figure 4B ). We also generated primary SMC cultures from MA of mice carrying a transgene consisting of (1) the CMV early enhancer/chicken β actin promoter/enhancer followed by a stop signal (loxP-STOP-loxP), Figure 4C ). We previously showed that expression of regulator of G-protein signaling 5 and Prkg2 was robustly altered in MA from S-P467L mice, and this was recapitulated in Ad-Cre-infected cells ( Figure S6 ). 11 Expression of TIMP-4 was markedly downregulated in cells after induction of P467L PPARγ ( Figure 4C ).
To determine whether TIMP-4 is a direct transcriptional target of PPARγ, we searched for PPARγ-binding sites (PPREs) within 10 kb of the TIMP-4 transcriptional start site. Two potential PPREs were identified downstream of TIMP-4, within intron 4 of the SYN2 gene in which the entire TIMP-4 gene is embedded ( Figure 5A ). 20, 21 Expression of SYN2 was not altered in S-P467L (fold change from nontransgenic; aorta: 0.96, P=0.5; MA: 0.99, P=0.6), suggesting that regulation of TIMP-4 expression is distinct from SYN2. Both PPREs are conserved and show high similarity with a consensus PPRE ( Figure 5A ). The binding of endogenous PPARγ (Ad-GFP) or Ad-P467L-transduced PPARγ at the PPRE closer to TIMP-4 promoter (PPARG-1) was examined in SMCs by chromatin immunoprecipitation. The P467L mutation does not impair DNA binding and has been reported to stabilize the corepressor complex. 22 As a control, P467L PPARγ physically interacted with a PPRE at the fatty acid-binding proteins-4 locus, a known PPARγ transcriptional target ( Figure 5B ). Binding of PPARγ at the PPARG-1 PPRE downstream of TIMP-4 was observed ( Figure 5C ), consistent with chromatin immunoprecipitation sequencing studies in 3T3-L1 adipocytes (National Center for Biotechnology Information accession GSE13511).
Given that TIMP-4 is an inhibitor of MMP, we evaluated the total MMP activity after PPARγ inhibition using in situ zymography. The same concentration of GW9662 that caused a robust reduction of TIMP-4 significantly increased net MMP activity in SMCs ( Figure 6A ). Inhibition of MMP activity using EDTA significantly blunted the fluorescent signal, suggesting that the enzymatic activity observed is specific to MMP. We next used the scratch assay to examine cell migration because it allows direct evaluation of cell-matrix and cell-cell interactions. 23 SMCs transfected with human TIMP-4 migrated significantly slower than those with an empty vector ( Figure 6B ). TIMP-4 did not affect SMC proliferation as assessed by expression of a cell proliferation marker (proliferating cell nuclear antigen; Figure S7A ). Stably expressing mutant P467L PPARγ by Cre-mediated activation of inducible PPARγ (and tdTomato) transgene in mesenteric SMCs downregulated TIMP-4 ( Figure 6C ) and led to a robust increase in migration compared with SMCs derived from a similar Cre-inducible transgene overexpressing wildtype PPARγ (Figure 6C ), without affecting cell proliferation ( Figure S7B ).
Discussion
Originally known for its requirement in adipogenesis, PPARγ also exerts specific functions outside adipocytes. Targeted inhibition of PPARγ activity in smooth muscle or endothelial cells leads to vascular dysfunction and changes in BP, thus underscoring the direct actions of PPARγ in the vasculature. 2 However, it remains unclear what genes are regulated by PPARγ and the mechanisms by which they confer cardiovascular protection. This study highlights the significance of smooth muscle PPARγ during salt-sensitive hypertension. The main conclusion of the study is that interference with smooth muscle PPARγ predisposes to vascular dysfunction and remodeling during DOCA-salt-induced hypertension through a mechanism involving robust downregulation of a novel PPARγ target, TIMP-4, and increased MMP activity. Our data are consistent with previous studies showing that TIMP-4 protein expression was significantly increased in the medial layer of the rat carotid artery undergoing vascular injury and that overexpression of TIMP-4 resulted in inhibition of SMC migration without affecting proliferation. 24 ,25 We previously demonstrated that smooth muscle PPARγ is important in maintaining arterial function, baroreflex, and systemic BP using S-P467L mice. [9] [10] [11] [12] 15 However, unlike previous cohorts, we did not observe an increase in BP in S-P467L mice at baseline in this study although we examined multiple independent cohorts of S-P467L mice. Although reason for this remains unclear, we offer 2 possibilities. First, the previously reported increase in arterial pressure was modest (≈7-10 mm Hg). 9, 15 Second, the present cohorts of mice have been backcrossed to C57BL/6 for ≈20 generations, many more than the mice used in our previous studies. Systemic BP has been reported to be lower in C57BL/6, and the genetic background has been shown to influence BP in other mouse models. 26, 27 Regulation of BP is complex and involves a combination of mechanisms, including central nervous system, kidney, immune, and vasculature. Interestingly, the tachycardia we previously reported in S-P467L mice was preserved in each of the cohorts used in this study. Similarly, aortic dysfunction and enhanced myogenic tone in mesenteric and middle cerebral artery remain robust in recent cohorts of S-P467L mice (data not shown). Thus, it remains possible that the elevation of BP in S-P467L observed previously is attenuated by some compensatory mechanisms. Nonetheless, S-P467L mice are more susceptible to the development of DOCA-salt hypertension.
DOCA-salt hypertension is a low renin model of essential hypertension. Low renin hypertension accounts for ≈27% of hypertensive patients and is more prevalent in blacks. 28, 29 Typically, high-dose DOCA is combined with reduced kidney mass and high salt intake to induce robust hypertension and consequent end-organ damage. 30, 31 Herein, we used a mild DOCA-salt hypertension protocol that uses low-dose DOCA without uninephrectomy, which induces a modest and gradual increase in BP. [29] [30] [31] [32] The rationale was to unmask a predisposition to hypertension caused by the loss of smooth muscle PPARγ. The role of decreased TIMP-4 in mediating the BP response to DOCA-salt treatment would require further investigation. Interestingly, there is no difference in the pressor response angiotensin II infusion in TIMP-4 knockout. 33 Our data strongly suggest that the marked reduction of TIMP-4 in S-P467L arteries is a direct consequence of interference of PPARγ activity in smooth muscle, and therefore, TIMP-4 is a direct transcriptional target of PPARγ. The evidence for this is 2-fold. First, direct inhibition of PPARγ activity in SMC culture either by expressing dominantnegative PPARγ or treatment with GW9662 led to a marked downregulation of TIMP-4. Second, we detected strong binding of PPARγ in chromatin at a PPRE in close proximity to the TIMP-4 gene in SMCs. On the basis of this result, it was surprising that thiazolidinedione treatment of primary SMC does not result in induction of TIMP-4 expression (data not shown). This suggests that PPARγ may simply be required for the maintenance of basal TIMP-4 expression. This conclusion is supported by the observation that dominant-negative PPARγ prevents the induction of TIMP-4 by DOCA-salt treatment. It is important to note that induction of PPARγ by thiazolidinediones both induces and represses gene expression. Such an effect has been reported in both adipocytes and in aorta by us. 8, 34 Indeed, not all PPARγ target genes are uniformly induced by thiazolidinediones. Indeed, the adverse effects of thiazolidinediones are likely due to massive activation of certain genes in the kidney, bone, and heart. In some cases, like TIMP-4, PPARγ may be required to maintain a basal level of expression. However, like those genes induced by thiazolidinediones, expression of genes, such as TIMP-4, will be impaired by mutants of PPARγ that cause human disease. This is because these mutations increase the occupancy of PPARγ on the PPRE and do not allow dismissal of corepressors. 35 It is also possible that other transcription factors in addition to PPARγ regulate TIMP-4 expression. Consistent with this, preliminary data from our laboratory suggested that TIMP-4 expression could be induced by aldosterone treatment in vascular SMC cultures. Genome-wide chromatin immunoprecipitation data from the Encode project provided evidence of binding of glucocorticoid receptor to the human TIMP-4 promoter, and within the same region, we identified 2 sequences similar to the hormone response element, which can be bound by either mineralocorticoid or glucocorticoid receptor.
Although the mechanism of PPARγ action has been extensively studied in adipocytes, the transcriptional targets in other tissues remain less well known. We previously unraveled the role of regulator of G-protein signaling 5 in resistance vasculature and identified it as a novel PPARγ target. 11 Recent studies have demonstrated beneficial actions of thiazolidinediones on vascular function in preeclampsia through upregulation of regulator of G-protein signaling 5, highlighting the importance of understanding the transcriptional targets of PPARγ in different tissues. 36 We cannot exclude the possibility that other genes beside TIMP-4 altered by interference with PPARγ activity in SMCs also contribute to exaggerated DOCA-salt-induced hypertension and vascular remodeling. Moreover, changes in other genes such as an induction of MMP-9 in S-P467L blood vessel after DOCA-salt treatment also likely contribute to increased vascular remodeling. Although the inhibitory effect of TIMP-4 on SMC migration seems modest, its significance is likely amplified during disease conditions. In particular, the failure to increase TIMP-4, attributable to the loss of smooth muscle PPARγ, and the concurrent increase in MMP-9 after DOCAsalt treatment can cause an imbalance in total MMP/TIMP activity, favoring increased SMC migration and vascular remodeling. In line with this, TIMP-4-deficient mice exhibit high mortality rates after myocardial infarction.
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Perspectives
Arterial remodeling occurring during hypertension and type 2 diabetes mellitus contributes to end-organ damage and serious cardiovascular complications. 38, 39 Activation of PPARγ by thiazolidinediones reduces vascular hypertrophy, lowers systemic BP, and lessens cardiovascular risks. 40 Conversely, the loss of PPARγ function results in enhanced smooth muscle migration and small blood vessel remodeling by unclear mechanisms. 7, 41 Accumulating evidence indicates that PPARγ exerts vascular protection through regulation of its transcriptional targets in endothelium and SMCs. Herein, we demonstrated a novel mechanism by which smooth muscle PPARγ regulates migratory phenotype of SMCs and arterial remodeling during salt-sensitive hypertension through TIMP-4. We focused on the function of TIMP-4 because its change in expression was among the most robust, and there was a logical rationale for its involvement in vascular remodeling. We validated TIMP-4 as a new PPARγ target and showed that specific suppression of TIMP-4 by mutant PPARγ is functionally associated with increased SMC migration and enhanced total MMP activity (model is given in Figure 6D ). The failure to increase TIMP-4 caused by defective PPARγ during hypertension was associated with augmented arterial remodeling and an exaggerated increase in BP. Further studies should address whether the beneficial effect of PPARγ activation on BP requires TIMP-4. Impaired PPARγ activity reported frequently in diabetes mellitus and hypertension might be associated with reduced vascular TIMP-4 and that might be an underlying mechanism of increased blood vessel stiffness and microvascular remodeling associated with end-organ damage. Our current studies shed light on a therapeutic potential of TIMP-4 during hypertension and provide a previously unrecognized link between PPARγ and TIMP-4.
• Augmented vascular remodeling in these mice was associated with suppressed tissue inhibitor of metalloproteinase (TIMP-4) expression.
• The expression of TIMP-4 was inversely correlated with the level of smooth muscle cell migration.
• We identified TIMP-4 as a new PPARγ target gene in smooth muscle cells.
What Is Relevant?
• Activation of PPARγ by thiazolidinediones reduces blood pressure, but the loss of PPARγ function is associated with hypertension. However, the mechanism remains unclear.
Summary
Our current studies identify a potential mechanism by which PPARγ exerts vascular protective effects in hypertension and vascular injury through activation of TIMP-4. Impaired PPARγ causes a decrease in TIMP-4 and increase in MMP-9 leading to remodeling.
